COMP <GO>
HRMY vs VERA // ENTERPRISE SCALE & MARKET CAP
Harmony Biosciences Holdings Inc. (NASDAQ) VS. Vera Therapeutics Inc. (Class A) (NASDAQ) • 15-METRIC TALLY: HRMY 4
— VERA 1
▲ ENTERPRISE SCALE & MARKET CAP LEADER: HRMY
LAST: $37.91 (-2.19%) • MKT CAP: $2.26B
market-cap
$2.26B
LAST: $30.25 (-2.36%) • MKT CAP: $2.23B
market-cap
$2.23B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HRMY VS. VERA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HRMY | VERA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 77.20% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 63.00% | -35.00% | +98.00 | HRMY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 7.8x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 15.48% | -10.99% | +26.47 | HRMY | /fcf-yield <GO> |
| Operating Margin | 24.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | 18.30% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 21.50% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.38 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 2/9 | +7.00 | HRMY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.1 | 52.7 | -1.60 | VERA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 11.9x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $2.26B | $2.23B | $24.7M | HRMY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HRMY REV | VERA REV | HRMY GROSS % | VERA GROSS % | HRMY FCF | VERA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $868.5M | $883.3M | 77.2% | — | $347.9M | -$241.7M |
| FY 2024 | $714.7M | $468.1M | 78.1% | — | $218.7M | -$135.7M |
| FY 2023 | $582.0M | $285.6M | — | — | $219.4M | -$92.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HRMY // BETA —
VERA // BETA —